AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
LONDON: AstraZeneca today announced $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end...
AstraZeneca announces $1.5 billion investment in Singapore manufacturing
LONDON: AstraZeneca has unveiled plans to construct a state-of-the-art manufacturing facility in Singapore, dedicated to the production of antibody drug conjugates (ADCs). This $1.5 billion...
EU Panel endorses AstraZeneca’s breast cancer drug Truqap
LONDON: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca’s drug Truqap, in combination with Faslodex,...
Angle plc signs new commercial agreement with AstraZeneca
LONDON: ANGLE plc (AIM:AGL), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology...
AstraZeneca to acquire Fusion Pharmaceuticals in a $ 2.0 billion deal
LONDON: AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a...
AstraZeneca enters definitive agreement to acquire Amolyt Pharma for $1.05 billion
AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine...
AstraZeneca reports strong growth in 2023 despite COVID-19 challenges
AstraZeneca, a global biopharmaceutical company, announced its financial results for the full year 2023, showing a 6% increase in total revenue and a 15% increase...
AstraZeneca to buy Gracell Biotechnologies for up to $1.2bn to boost cell therapy pipeline
Acquisition of Gracell completed AstraZeneca has agreed to acquire Gracell Biotechnologies, a company developing cell therapies for cancer and autoimmune diseases, for up to $1.2bn....
AstraZeneca signs deal to acquire Icosavax Inc. for $1.1 billion
LONDON, UK: AstraZeneca has entered into a definitive agreement to acquire Icosavax Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential...
AstraZeneca’s Truqap approved in US for advanced breast cancer
LONDON: AstraZeneca announced that its drug Truqap (capivasertib) has received approval from the US Food and Drug Administration (FDA) for the treatment of a specific...
AstraZeneca and Cellectis partner to accelerate development of next-generation therapeutics
LONDON, UK: AstraZeneca (NYSE: AZN) today announced a collaboration and investment agreement with Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company, to accelerate the development of...
AstraZeneca settles Nexium and Prilosec product liability litigations
LONDON, UK: AstraZeneca has entered into settlement agreements in the product liability litigations related to Nexium and Prilosec. AstraZeneca will make payment of $425 million,...